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The objective of this study was to document the occurrence and to correlate the prevalence of different human papillomavirus
(HPV) types with the cytological results on simultaneously performed thin-layer preparations in a large population of Flemish women.
During 1 year, 69 290 thin-layer preparations were interpreted using the Bethesda classification system. Using an algorithm for HPV
testing based on consensus primers and type-specific PCRs in combination with liquid-based cytology, we determined the occurrence
and distribution of 14 different oncogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). Reflex HPV testing was
performed on cytologically abnormal samples and on an age matched randomly selected control group with normal cervical cytology
(n¼1351). Correlation between cytology, age and prevalence for the 14 different high-risk HPV types is given. There is a significant
increase in predominance of high-risk HPV types, with increasing abnormal cytology. Coinfection with multiple HPV types also
increased with cytological abnormalities, and was highest in HSIL (16.7%). In Flanders, HSIL was most often associated with HPV types
16, 33, 35, 31, 18 and 51. Using thin-layer liquid-based cytology and PCR to detect HPV, it is feasible to screen large numbers of
women.
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During recent years, there has been increasing evidence implicating
infection with high-risk human papillomavirus (HPV) as a causal
factor in the development of cervical intraepithelial neoplasia and
invasive carcinoma (Kiviat and Koutsky, 1993; Schiffman et al,
1993; IARC Working Group, 1995; Bosch et al, 2002). The presence
of HPV in virtually all cervical cancers implies the highest
worldwide attributable fraction so far reported for a specific cause
of any major human cancer (Walboomers et al, 1999). Worldwide
cervical cancer remains the second most common cancer in women
(Parkin et al, 2001). In Belgium cervical cancer ranks fifth after
breast, colon, ovarium and rectum cancer (Arbyn and Van Oyen,
1999; National Cancer Register, 2000).
More than 40 genital HPV types have been shown to infect the
genital mucosa and have been characterised (IARC Working
Group, 1995). Recent studies have shown that in addition to HPV
16 and 18, HPV types 31, 33, 35, 45, 51, 52, 58 and 59 should be
considered as human carcinogens (Bosch et al, 2002). The
potential role of HPV testing in cervical cancer screening
programmes has been under consideration for several years
(Cuzick et al, 1994; Jenkins et al, 1996) and is felt to be promising
for a triage of women with atypical squamous cells of undeter-
mined significance (Solomon et al, 2001; Arbyn and Van Ranst,
2002). Identification of high-risk HPV genotypes may permit
selection of patients who are at increased risk for disease (Cuzick
et al, 1995). For women with low-grade squamous intraepithelial
lesions there is only a limited potential for triage with HPV DNA
testing because a very high percentage of these women were shown
to be HPV positive (ALTS group, 2000; Stoler, 2001). However,
detection of type-specific HPV DNA in abnormal smears could be
used as a more specific predictor of high-grade cervical
intraepithelial neoplasia (Cuzick et al, 1994).
We used the MY09/MY11 L1 consensus primer-based PCR
(Bauer et al, 1991), in combination with 14 type-specific PCRs
(Walboomers et al, 1999), to determine the prevalence of different
oncogenic HPV types in a group of women with normal and
abnormal cervix cytology. Owing to its complex politico-admin-
istrative structure, Belgium can be divided into three geographi-
cally separated regions. The Flemish region, with a female
population of 3.0 million, the Walloon region with 1.7 million
women and the Capital region of Brussels with 0.5 million women.
A programme for organised screening, based on the European
guidelines, only exists in the Flemish community (Arbyn and Van
Oyen, 2000). The aim of the study was to document the occurrence
and distribution of HPV types in a population of Flemish women,
and to correlate the prevalence of different HPV types with the
cytological results on simultaneously performed thin-layer pre-
parations.
MATERIALS AND METHODS
Sample processing and cytological procedure
For thin-layer liquid-based cytology preparations (LBP), cervical
samples were collected using the Cervex-Brush
s (Rovers, Oss, The
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yNetherlands). After collection, brush heads were transferred
directly into alcohol-based preservative (AutoCyte
s, Tripath
Imaging Inc, Burlington, NC, USA), and the vials were transported
to the laboratory. The LBP were made with the fully robotic
AutoCyte
s PREP System (AutoCyte
s, Tripath Imaging Inc,
Burlington, NC, USA) (Vassilakos et al, 1999), and were prepared
as described elsewhere (Vassilakos et al, 1998). All slides were
manually screened by cytotechnologists who are intensively
trained in the evaluation of thin-layer slides. Five percent of all
LBPs (quality control), as well as all positive and suspicious cases
were reviewed by senior cytotechnologists and forwarded for final
diagnosis to one of the pathologists (KS, JJB), who were unaware of
the subject’s HPV DNA status. The cytological results were
classified according to the Bethesda system (Kurman and
Solomon, 1996), using the classes within normal limits (WNL),
atypical squamous cells of undetermined significance (ASCUS),
low-grade squamous intraepithelial lesions (LSIL) and high-grade
squamous intraepithelial lesions (HSIL).
Screening procedure and patients
Between July 2000 and June 2001, the Laboratory for Clinical
Pathology (Labo RIATOL, Antwerp, Belgium) received 69 290
cervical samples for cytological evaluation from women that were
taken by general practitioners and gynaecologists in Flanders
(Belgium).
HPV DNA reflex testing was performed on all cytologically
abnormal samples. For cytological normal samples, HPV DNA
testing was performed only on explicit request of the clinician
(WNLr), and on a randomly selected representative control group
of 100 samples with normal cervical cytology (WNLc) of women
with the same age distribution as the total group.
Study-specific patient identification codes were assigned and
transmitted in such a manner that patient confidentiality was
preserved.
Isolation of DNA from cervical cells
After thin-layers were made, 400ml of the remaining cells
suspension was transferred to an eppendorf tube and cells were
pelleted by centrifugation. The supernatant was discarded and the
pellet resuspended in 50ml digestion solution (10mM Tris, 1mM
EDTA, 200mgm l
 1 Proteinase K) and digested for 3h at 551C. The
digestion was followed by a 10min incubation at 951C to inactivate
the proteinase K. The DNA extracts were stored at  201C until
PCR was performed.
Positive and negative controls for PCR analysis
Several precautions were taken to prevent false positive results.
Different steps such as DNA extraction, sample preparation,
amplification and post-PCR were performed in strictly separated
rooms. Aerosol-resistant pipette tips were used for all handling of
liquids. In all runs, distilled water samples were included as
negative PCR controls. As positive control samples, HPV-contain-
ing cell lines SiHa (ATCC, HTB-35), containing 1 copy of HPV-16/
cell, and Hela (ATCC, CCL-2) containing 10–50 HPV-18 copies/
cell were used.
HPV detection and typing by PCR
PCR using consensus primers MY09/MY11 allowed the production
of 450bp fragments in the L1 region (Bauer et al, 1991). Specimens
positive with the consensus PCR were assayed with E7 type-
specific primers for high-risk HPV types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66 and 68 (van den Brule et al, 1990), and were
done in sequence (Walboomers et al, 1999). We tested for HPV
types 45, 52, 56, 58, 59 and 68 only in patients who where HPV type
16, 18, 31, 33, 35, 39, 51 and 66 negative. Cases in which general
primer PCR was positive, but negative in the type-specific PCRs,
were considered to contain presently unidentified HPV genotypes
and were denoted HPV X. Samples negative for the consensus PCR
were subjected to a control PCR for b-globin with GH20 and PC04
primers (Manos et al, 1989) and type-specific PCRs for HPV types
18, 35, 39, 51 and 66. A measure of 10ml of each PCR product was
electrophoresed in a 3% agarose gel and stained with ethidium
bromide. Three experienced investigators interpreted each result,
and discrepancies were resolved by consensus.
Statistical analysis
Comparisons of means was studied by analysis of variance
(ANOVA), followed by Student–Newman–Keuls test for all
pairwise comparisons. The w
2 statistics for trend was used to
verify the existence of a trend across ordered groups (such as
increase in HPV positivity) according to the degree of cytological
abnormality. Statistical tests were considered significant at
Po0.05. Statistical analysis was performed using the MedCalc
s
program (MedCalc Software, Mariakerke, Belgium) (Schoonjans
et al, 1995).
RESULTS
From a total of 69 290 samples, 19 (0.03%) were inadequate, 67 474
(97.38%) had normal cytology, 992 (1.43%) were classified as
ASCUS, 641 (0.93%) as LSIL and 164 (0.24%) as HSIL. In total,
1797 (2.59%) samples were classified as abnormal (Table 1). The
mean age of the total screened population was 40.3 years.
Surprisingly, the mean age of the LSIL group (32.9 years) was
significantly lower (Po0.05) compared to all other groups.
Table 1 Baseline characteristics of the different cytologic groups according to the Bethesda classification
Whole group HPV-tested group
Bethesda n Mean age s.d. Range n Mean age s.d. Range
WNL 67474 40.4 13.1 13–95 100
c, 193
r 40.1 13.1 17–85
ASCUS 992 38.0 13.0 16–87 552 37.2 12.4 16–78
LSIL 641 32.9 11.0 16–78 369 32.9 10.9 17–74
HSIL 164 39.3 11.5 19–79 137 39.7 11.8 21–77
Total 69290* 40.3 13.1 13–95 1351 40.3 12.3 16–85
WNL=within normal limits; c=control group; r=tested on request of clinician; ASCUS=atypical squamous cells of undetermined significance; LSIL=low-grade squamous
intraepithelial lesions; HSIL=high-grade squamous intraepithelial lesions; s.d.=standard deviation; *=19 samples were inadequate.
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tested because the clinician did not want HPV reflex testing on
abnormal samples, and 610 samples of women who were tested
shortly before were excluded from the study population. Ulti-
mately 1058 abnormal samples were included, 552 ASCUS, 369
LSIL and 137 HSIL cases. Also, 193 samples with normal cytology
were tested for HPV DNA on explicit demand of the clinician
(Table 1). Also for the HPV DNA-tested samples, the mean age of
the LSIL group (32.9 years) was significantly lower (Po0.05)
compared to all other groups. There was no significant difference
in age between the cytologic groups tested for HPV and cytologic
groups of the whole group (P40.05).
HPV DNA positivity
Using the consensus PCR as a first step for triage, 818 samples
revealed to be positive for HPV DNA (Figure 1). In 12 samples
from the 533 samples that tested negative for the consensus PCR,
no b-globin could be amplified, and 57 tested positive for HPV
types 18, 35, 39, 51 or 66. HPV51 was the most frequent type that
was not detected by the consensus PCR (71.9%), followed by
HPV39 (12.3%), HPV18 and 35 (7.0%), and HPV66 (3.5%). When
we consider the number of samples tested in each cytological
diagnosis group, the number of consensus PCR-negative samples,
but containing HPV types 18, 35, 39, 51, 66, was most frequent in
the LSIL (8.9%) and HSIL (4.5%) groups (Table 2). Finally, taking
into consideration samples positive with type-specific PCRs but
consensus PCR negative, overall 464/533 samples tested negative
for HPV (Figure 1).
Typing of consensus positive samples with a first multiplex PCR
detecting HPV types 16, 31, 33 and 35 revealed that more than half
of the tested samples (429 out of 818; 52.4%) were positive for one
of these HPV types. Subsequent typing of the remaining 389
samples with multiplex PCRs for types 18, 39, 51 and 66 showed
that 52.2% (203 out of 389) of samples contained these oncogenic
HPV types. From the remaining 186 untyped samples, only 45 were
positive when tested with type-specific PCRs for HPV types 45, 52,
56, 58, 59 and 68. Ultimately, 141 samples were negative for all
type-specific PCRs and were considered to contain presently
unidentified HPV genotypes of unknown malignant potential
(HPV X).
The overall HPV prevalence and type distribution according to
cytological diagnosis is given in Table 3. The 12 samples that tested
negative for b-globin DNA were excluded from further analysis.
Using HPV consensus L1 and E7 type-specific PCRs, the total
number of HPV-positive samples was 875 out of 1339 (65.4%).
Overall, HPV was detected in 21% of the samples of the WNLc
group, in 25.7% of the WNLr group, in 58.7% of the ASCUS group,
in 95.4% of the LSIL group and in 98.5% of the samples in the HSIL
group (w
2 for linear trend¼440, Po0.0001). The percentage of
HPV-positive samples infected with only one HPV type in the
WNLc and the WNLr group was 19.0 and 25.1%, respectively, and
was not significantly different (P40.2). There was a significant
increase in samples with single HPV infection with increasing
abnormal cytology (w
2 for linear trend¼289, Po0.0001). The
percentage of samples infected with multiple HPV types was low in
the control group (2.0%) and did not differ significantly (P40.9)
from the percentage found in the WNLr group (0.5%). There was a
significant increase in samples infected with multiple HPV types
PCR +
=> high risk HPV
429 (31.8%)
PCR  +
=>high risk HPV
203 (15.0%)
PCR +
=> high risk HPV
45 (3.3%)
PCR -
=> low risk HPV
141 (10.4%)
PCR for
HPV 45,52,56,58,59,68
PCR  -
other HPV type
186 (13.8%)
PCR for
HPV 18, 39, 51, 66
PCR -
other HPV type
389 (28.8%)
PCR for
HPV 16, 31, 33, 35
Consensus PCR +
818 (60.5%)
HPV - / -globin +
=> HPV negative
464 (34.3%)
HPV 18,35,39,51,66  +
=> high risk HPV
57 (4.2%)
-globin -
=> no ampl. DNA
12 (0.9%)
control PCR
-globin / HPV 18,35,39,51,66
Consensus PCR -
533 (39.5%)
Consensus PCR
n =1351
Figure 1 Algorithm for HPV PCR testing.
Table 2 Overall HPV prevalence and type distribution detected by type-
specific PCRs of consensus PCR-negative samples according to cytological
diagnosis
HPV type WNLc WNLr ASCUS LSIL HSIL
18 FF 12 F
18,39 FF F F1
35 F 1 F 21
39 F 22 2 F
51 1 1 10 26 3
66 FF F 11
Total HPV + 1 4 13 33 6
Tested/group 100 187 549 369 134
Per cent +/group 1.0 2.1 2.4 8.9 4.5
For abbreviations see footnote in Table 1.
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group (w
2 for linear trend¼48, Po0.001). A linear trend was also
found in samples infected with high-risk HPV types with
increasing abnormal cytology (w
2 for linear trend¼78, Po0.001).
Distribution of HPV types according to cytology
In the WNLc control group only a limited number of oncogenic
HPV types were detected, namely HPV 16, 18, 31, 35, 39 and 51
(Table 3). The HPV types in the WNLr group were very similar,
with only additional HPV types 33 and 52 being detected. The
greatest HPV-type heterogeneity was seen in the ASCUS group,
where almost all oncogenic types were detected except for HPV68.
HPV types 58 and 59 were only detected in the ASCUS group. Also
in the group with low-grade lesions, there was a great HPV-type
heterogeneity. The type spectrum in the high-grade lesions is more
restricted and is comparable with the types detected in the WNLr/
WNLc groups. In the HSIL group, HPV types 16, 18, 31, 33, 35, 39,
45, 51 and 52 accounted for almost 97% of all types found. From
the 818 consensus PCR-positive samples, 141 were negative for all
type-specific PCRs and were considered to contain presently
unidentified HPV genotypes of unknown risk potential (HPV X).
The prevalence for each individual HPV type as a function of
increasing abnormal cytology is shown in Figure 2. For HPV types
16, 33, 35 and 45 there was an increasing prevalence with
increasing abnormal cytology, with the highest prevalence in the
HSIL group. For HPV types 66, 56, 51 and 31, the highest
prevalence was observed in the LSIL group. The highest prevalence
for HPV18 was seen in the ASCUS group, for HPV type 52 in both
the ASCUS and HSIL groups and for HPV39 and HPVX in the
WNLr and WNLc groups, respectively. The prevalence of
unidentified HPV types decreased with increasing abnormal
cytology. Patients with ASCUS were younger than patients with
LSIL for HPV types 16, 31, 35, 51 and 56. For HPV types 18, 33, 39,
45, 52 and 66 patients with ASCUS were older than patients with
LSIL.
Age and HPV prevalence
The mean age of the different cytologic groups according to HPV
DNA positivity is given in Table 4. In the WNLr and ASCUS
groups, HPV-positive patients were significantly younger than
HPV-negative patients (Po0.05). Whereas in the WNLc, LSIL and
HSIL groups no significant difference in age between HPV-positive
and HPV-negative patients was observed. Patients with LSIL
smears were always the youngest irrespective of their HPV status.
DISCUSSION
Each year approximately 1 200 000 cervical smears are taken in
Belgium, of which 660 000 come from women living in Flanders
(Arbyn and Van Oyen, 1999). Between July 2000 and June 2001,
69290 thin-layer cytology preparations were processed in our
laboratory, representing almost 11% of all smears taken in
Flanders during that period.
Using an algorithm for HPV testing based on consensus primers
and type-specific PCRs in combination with liquid-based cytology,
we determined the occurrence and distribution of 14 different
oncogenic HPV types in a population of Flemish women.
Methodological considerations
Thin-layer liquid-based cervical cytology One advantage of using
liquid cytology for the collection of cervical specimens is that
multiple diagnostic tests can be performed on a single sample
avoiding recall of women for additional testing. The technique can
be easily automated and combined with HPV testing on a large
number of samples. For samples diagnosed as ASCUS, LSIL or
HSIL, HPV testing can be performed on the remaining stored
liquid cytology specimen without the cost of a clinical follow-up
visit. Furthermore, only in a small number of samples b-globin
DNA could not be detected. Therefore, the CytoRich fixative
provides an excellent preservation of the samples making a simple
and cheap DNA extraction possible. Liquid-based cytology
improves the overall adequacy of the cell sampling, smearing
and staining, as seen by the low number of samples judged as
inadequate (0.03%) or interpreted as ASCUS (1.43%). Overall,
2.6% of the smears were classified as abnormal. This is within the
range observed in other Flemish cytological laboratories (Arbyn
et al, 1999). Finally, supplementing HPV detection to liquid-based
cytology in a single combined test makes available an indicator for
the quality assurance of abnormal cervical cytology. Our
cytological diagnostic accuracy appears consistent with the HPV
detection, since a high percentage (76.6%) of abnormal samples
are HPV positive.
HPV detection As previous studies have shown, the MY09/11
primers preferentially amplify certain HPV types (Walboomers
et al, 1999; Gravitt et al, 2000), therefore all consensus negative
Table 3 HPV prevalence and type distribution according to cytological
diagnosis
HPV type WNLc WNLr ASCUS LSIL HSIL
16 1 9 61 65 55
16,31 FF F 2 F
16,31,35 1 F 32 2
16,33 FF 32 5
16,35 1 F 44 5
18 1 3 30 20 5
18,39 F 12 F 2
18,66 FF F 2 F
31 FF 16 F
31,33,35 FF 1 FF
31,35 FF 14 29 7
33 F 53 2 3 9 2 2
33,35 FF 12 1
35 F 51 9 1 5 9
39 1 7 25 32 2
45 FF 11 2
51 2 3 28 45 7
52 F 19 3 4
56 FF 51 5 F
58 FF 3 FF
59 FF 1 FF
66 FF 92 81
68 FF F F F
X1 4 1 4 7 0 4 0 3
S 16 3 9 71 75 67
S 18 1 4 32 22 7
S 31 1 F 19 39 9
S 33 F 53 7 4 3 2 8
S 35 2 5 42 52 24
S 39 1 8 27 32 4
S 66 FF 93 01
Total HPV + 21 48 322 352 132
Single type 19 47 294 309 112
Multiple types 2 1 28 43 22
High-risk type(s) 7 34 252 312 129
Total tested/group 100 187 549 369 134
S=total number of samples positive for the specified HPV type; X=HPV types
different from HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
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66. Not unexpectedly HPV51 was the most frequent type that was
not detected by the consensus PCR, followed by HPV39 and 35. It
has been shown that the addition of an extra sequence-specific
oligonucleotide (HMB01) directed to the minus strand of
HPV type 51 facilitates the amplification of this important
cancer-associated type of HPV (Hildesheim et al, 1994). The
MY09/11 PCR targets a 450bp fragment within the HPV L1
open reading frame. Failure to detect HPV DNA may have been
because of the lack of specificity for certain HPV types (Gravitt
et al, 2000), such as HPV51, 35 and 39. A second possibility is
that the MY09/11 primers failed to amplify HPV DNA because of
the loss of the HPV L1 open reading frame due to integration
of HPV DNA into the host genome (Walboomers et al, 1999).
This is particularly true for HPV18. Previous studies have
shown that HPV18 is more often disrupted in the L1 region
than other HPV types (Berumen et al, 1994; Walboomers et al,
1999).
HPV-type prevalence The type spectrum in the high-grade
lesions is much more restricted compared to ASCUS and LSIL,
with HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 58 and 59
accounting for nearly 97% of HPV types detected in HSIL. This is
in agreement with other studies (Bosch et al, 2002), where the HPV
DNA prevalence in HSIL using PCR-based methods varies from 75
to 100%.
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Figure 2 Prevalence for each HPV type according to cytological diagnosis.
Table 4 Mean age of the different cytologic groups according to HPV DNA positivity (HPV DNA-tested group)
Bethesda HPV n Mean age s.d. Range Different (Po0.05) from
WNLc   79 41.2 13.4 17–74 LSIL
+ 21 36.1
NS 11.0 20–55
WNLr   139 41.3 12.0 17–79 LSIL
+ 48 37.1
a 13.5 18–85 LSIL
ASCUS   227 41.1 12.4 18–78 LSIL
+ 322 34.4
b 11.7 16–75 LSIL*, HSIL
LSIL   17 33.7 11.5 17–57 WNLc, WNLr, ASCUS, HSIL
+ 352 32.8
NS 10.9 17–74 WNLr, ASCUS*, HSIL
HSIL   2 55.0 4.2 52–58 LSIL
+ 132 39.4
NS 11.8 19–77 ASCUS, LSIL
Total   464 41.0 12.5 17–79
+ 875 34.7
b 11.7 16–85
aSignificantly younger than the HPV-negative samples (Po0.04).
bSignificantly younger than HPV-negative samples (Po0.0001). NS=not significantly younger than HPV-negative
samples (P>0.05). *Po0.07. For other abbreviations see Table 1.
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HPV16 is the most common virus at the cervix regardless of the
cytological diagnosis.
The overall HPV-type distribution in HSIL was similar to that
in squamous cell carcinoma, but type distribution was dissimilar
in one aspect. HPV18 was not the first or second most frequent
high-risk type but rather the fourth or fifth. This is in accordance
with studies from Mexico and Canada using the same MY09/11
PCR (Torroella-Kouri et al, 1998; Feoli-Fonseca et al, 2001).
This deficit of HPV18 in high-grade lesions has been observed
previously (Lo ¨rincz et al, 1992), and it has been suggested
that HPV18-associated cervical disease is more rapidly progres-
sive, with a short duration for the HSIL lesion (Kurman et al,
1988). This is in agreement with our finding that the prevalence
for HPV18 is highest in ASCUS and lower in LSIL and HSIL
groups. Remarkable is the fact that women with LSIL infected with
HPV18 are on average 5 years younger than patients with ASCUS
infected with the same virus. From the above, it could be argued
that LSIL is a separate end point in the disease caused by HPV
infection.
Although the overall prevalence of HPV in the HSIL group
(98.5%) is high, not all samples were positive. Previous studies on
HPV-type prevalence in Belgium were carried out only in the
female population of Antwerp on DNA extracted from paraffin-
embedded tissue (Baay et al, 2001). Using the GP5+/6+ consensus
primer they showed only a prevalence of 77% in cervical
intraepithelial neoplasia (CIN), and 88% in cervical carcinoma.
This could be because of the specific viral types, viral load or
choice of samples. It is easier to extract HPV DNA from cytological
samples than from paraffin-embedded biopsy samples. Further-
more, we found an increase in multiple infections with increasing
abnormal cytology and the MY-PCR system has been shown to
detect twice as much samples with multiple HPV types as
compared to the GP5+/6+ PCR system (Qu et al, 1997). This
difference in sensitivity to detect dysplasia stresses the need for
validation of a consensus primer set in each given population and/
or the use of simultaneous type-specific detection in some of the
negative samples. The prospective comparison of the two test
systems for the Belgian population will be part of a future study.
For LSIL cases the prevalence of HPV DNA is higher than 95%
but still lower than in HSIL cases. The higher amount of HPV-
negative LSIL cases could be explained by the fact that regression
of abnormal cytology occurs 3.6 months later than HPV clearance,
which may explain the presence of a lesion in the absence of HPV
DNA as was shown by recent Dutch studies (Nobbenhuis et al,
2001; Zielinski et al, 2001).
We found a lower prevalence (58.6%) in ASCUS cases. This is in
agreement with previous studies (Solomon et al, 2001; Arbyn and
Van Ranst, 2002).
In this study, the prevalence of women with a normal cytology to
be HPV positive was 21%, and is in agreement with other studies
in which the same MY09/MY11 PCR technique was used (26.0%,
Hildesheim et al, 1994; 17.0%, Torroella-Kouri et al, 1998; 25.1%,
Riethmuller et al, 1999).
We showed that in the Flemish population HPV types 16, 18, 31,
33, 35, 39, 45, 51, 52 and 66 are present in high-grade lesions,
contrary to a previous study conducted in Antwerp that detected
HPV39 and 51 only in low-grade lesions (Baay et al, 2001). We are
currently investigating differences in HPV-type prevalence in the
different provinces in Flanders, including Antwerp, to see whether
regional differences can explain this discrepancy.
Screening in Belgium is performed essentially at opportunistic
basis, characterised by overscreening in coexistence with
underscreening in indigent groups, heterogeneous quality, lack
of quality control and impossibility to document effectiveness of
screening by lack of adequate monitoring (Arbyn and Van Oyen,
2000).
Previous studies in the Netherlands have shown that there is a
clear relation between HPV positivity and severity of disease, and
that severe dyskaryosis is associated with persistent HPV
infections, whereas minor abnormalities are more often associated
with fluctuating or transient infections (Meijer et al, 1992).
HPV DNA detection allows a more effective triage of women
showing equivocal cytological results than repeat cytology
(Solomon et al, 2001; Arbyn and Van Ranst, 2002; Kim et al,
2002). In the case of LSIL, on the other hand, the discriminative
power of HPV triage is poor because of the very high prevalence of
HPV-positivity (95% in our study) (ALTS Group, 2000; Stoler,
2001). Nevertheless, HPV typing might make LSIL triage a
potential useful strategy that merits further investigation.
Our study confirms that polyvalent vaccines including the main
cancer-associated HPV types would be needed to prevent most
cases of cervical disease in the screened, high-risk population
(Herrero et al, 2000).
Finally, with this study we have proven that HPV typing is
feasible in a high-throughput or routine setting.
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